Madrigal Pharmaceuticals Inc (MDGL)
$304.50 -$2.70 (-0.89%) 10:54 PM 12/14/24
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$6.64B -
Day's Range
$295.02 - $308.65 -
Volume
306,172 -
52 Week Low / High
$168.25 - $368.29 -
PE Ratio
- -
PEG Ratio
- -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 9
- Strong Buy
- 4
- Buy
- 3
- Hold
- 1
- Sell
- 0
- Strong Sell
- $318.25
- Target Price
Company News
-
High Growth Tech Stocks To Watch In October 2024 — Oct 9th, 2024
Over the last 7 days, the United States market has remained flat but is up 30% over the past year with earnings forecast to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking at companies that not only show strong potential for revenue expansion...
-
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 — Oct 18th, 2024
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2024 financial results on Thursday, Oct. 31, 2024, prior to the open of the U.S. financial markets. F...
-
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 — Oct 18th, 2024
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2024 financial results on Thursday, Oct. 31, 2024, prior to the open of the U.S. financial markets. F...
-
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis — Oct 21st, 2024
Madrigal Pharmaceuticals, Inc. Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH cirrhosis, a population at high risk of progressing to adverse liver-related outcomes Study may also support full app...
-
Madrigal Pharmaceuticals (MDGL): Leading the NASH Treatment Revolution with Rezdiffra — Oct 16th, 2024
We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Madrigal Pharmaceuticals (NASDAQ:MDGL) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volat...
-
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis — Oct 21st, 2024
Madrigal Pharmaceuticals, Inc. Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH cirrhosis, a population at high risk of progressing to adverse liver-related outcomes Study may also support full app...
-
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH — Nov 1st, 2024
Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment. Continue reading View comments...
-
Madrigal Pharmaceuticals (MDGL): Leading the NASH Treatment Revolution with Rezdiffra — Oct 16th, 2024
We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Madrigal Pharmaceuticals (NASDAQ:MDGL) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volat...
-
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis — Oct 21st, 2024
Madrigal Pharmaceuticals, Inc. Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH cirrhosis, a population at high risk of progressing to adverse liver-related outcomes Study may also support full app...
-
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 — Oct 18th, 2024
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2024 financial results on Thursday, Oct. 31, 2024, prior to the open of the U.S. financial markets. F...
-
Madrigal Pharmaceuticals (MDGL): Leading the NASH Treatment Revolution with Rezdiffra — Oct 16th, 2024
We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Madrigal Pharmaceuticals (NASDAQ:MDGL) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volat...
-
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH — Nov 1st, 2024
Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment. Continue reading View comments...
-
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis — Oct 21st, 2024
Madrigal Pharmaceuticals, Inc. Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH cirrhosis, a population at high risk of progressing to adverse liver-related outcomes Study may also support full app...
-
Madrigal Pharmaceuticals (MDGL): Leading the NASH Treatment Revolution with Rezdiffra — Oct 16th, 2024
We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Madrigal Pharmaceuticals (NASDAQ:MDGL) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volat...
-
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH — Nov 1st, 2024
Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment. Continue reading View comments...
-
Madrigal Pharmaceuticals (MDGL): Leading the NASH Treatment Revolution with Rezdiffra — Oct 16th, 2024
We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Madrigal Pharmaceuticals (NASDAQ:MDGL) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volat...
-
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH — Nov 1st, 2024
Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment. Continue reading View comments...
-
High Growth Tech Stocks To Watch In October 2024 — Oct 9th, 2024
Over the last 7 days, the United States market has remained flat but is up 30% over the past year with earnings forecast to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking at companies that not only show strong potential for revenue expansion...
-
High Growth Tech Stocks To Watch In October 2024 — Oct 9th, 2024
Over the last 7 days, the United States market has remained flat but is up 30% over the past year with earnings forecast to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking at companies that not only show strong potential for revenue expansion...
-
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis — Oct 21st, 2024
Madrigal Pharmaceuticals, Inc. Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH cirrhosis, a population at high risk of progressing to adverse liver-related outcomes Study may also support full app...
-
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis — Oct 21st, 2024
Madrigal Pharmaceuticals, Inc. Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH cirrhosis, a population at high risk of progressing to adverse liver-related outcomes Study may also support full app...
-
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH — Nov 1st, 2024
Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment. Continue reading View comments...
-
Madrigal Pharmaceuticals (MDGL): Leading the NASH Treatment Revolution with Rezdiffra — Oct 16th, 2024
We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Madrigal Pharmaceuticals (NASDAQ:MDGL) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volat...
-
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis — Oct 21st, 2024
Madrigal Pharmaceuticals, Inc. Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH cirrhosis, a population at high risk of progressing to adverse liver-related outcomes Study may also support full app...
-
High Growth Tech Stocks To Watch In October 2024 — Oct 9th, 2024
Over the last 7 days, the United States market has remained flat but is up 30% over the past year with earnings forecast to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking at companies that not only show strong potential for revenue expansion...
-
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH — Nov 1st, 2024
Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment. Continue reading View comments...
-
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 — Oct 18th, 2024
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2024 financial results on Thursday, Oct. 31, 2024, prior to the open of the U.S. financial markets. F...
-
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH — Nov 1st, 2024
Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment. Continue reading View comments...
-
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis — Oct 21st, 2024
Madrigal Pharmaceuticals, Inc. Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH cirrhosis, a population at high risk of progressing to adverse liver-related outcomes Study may also support full app...
-
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis — Oct 21st, 2024
Madrigal Pharmaceuticals, Inc. Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH cirrhosis, a population at high risk of progressing to adverse liver-related outcomes Study may also support full app...
-
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH — Nov 1st, 2024
Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment. Continue reading View comments...
-
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 — Oct 18th, 2024
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2024 financial results on Thursday, Oct. 31, 2024, prior to the open of the U.S. financial markets. F...
-
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH — Nov 1st, 2024
Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment. Continue reading View comments...
-
Madrigal Pharmaceuticals (MDGL): Leading the NASH Treatment Revolution with Rezdiffra — Oct 16th, 2024
We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Madrigal Pharmaceuticals (NASDAQ:MDGL) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volat...
-
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH — Nov 1st, 2024
Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment. Continue reading View comments...
-
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 — Oct 18th, 2024
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2024 financial results on Thursday, Oct. 31, 2024, prior to the open of the U.S. financial markets. F...
-
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis — Oct 21st, 2024
Madrigal Pharmaceuticals, Inc. Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH cirrhosis, a population at high risk of progressing to adverse liver-related outcomes Study may also support full app...
-
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis — Oct 21st, 2024
Madrigal Pharmaceuticals, Inc. Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH cirrhosis, a population at high risk of progressing to adverse liver-related outcomes Study may also support full app...
-
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 — Oct 18th, 2024
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2024 financial results on Thursday, Oct. 31, 2024, prior to the open of the U.S. financial markets. F...
-
High Growth Tech Stocks To Watch In October 2024 — Oct 9th, 2024
Over the last 7 days, the United States market has remained flat but is up 30% over the past year with earnings forecast to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking at companies that not only show strong potential for revenue expansion...
-
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 — Oct 18th, 2024
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2024 financial results on Thursday, Oct. 31, 2024, prior to the open of the U.S. financial markets. F...
-
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH — Nov 1st, 2024
Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment. Continue reading View comments...
-
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH — Nov 1st, 2024
Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment. Continue reading View comments...
-
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 — Oct 18th, 2024
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2024 financial results on Thursday, Oct. 31, 2024, prior to the open of the U.S. financial markets. F...
-
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 — Oct 18th, 2024
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2024 financial results on Thursday, Oct. 31, 2024, prior to the open of the U.S. financial markets. F...
-
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH — Nov 1st, 2024
Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment. Continue reading View comments...
-
Madrigal Pharmaceuticals (MDGL): Leading the NASH Treatment Revolution with Rezdiffra — Oct 16th, 2024
We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Madrigal Pharmaceuticals (NASDAQ:MDGL) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volat...
-
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis — Oct 21st, 2024
Madrigal Pharmaceuticals, Inc. Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH cirrhosis, a population at high risk of progressing to adverse liver-related outcomes Study may also support full app...
-
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis — Oct 21st, 2024
Madrigal Pharmaceuticals, Inc. Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH cirrhosis, a population at high risk of progressing to adverse liver-related outcomes Study may also support full app...
-
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH — Nov 1st, 2024
Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment. Continue reading View comments...
Portfolio
Comprised of 1 portfolios